Burst Spinal Cord Stimulation in the Management of Chronic Pain: Current Perspectives.

Autor:	Edinoff AN; Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center, Shreveport, LA, USA., Kaufman S; Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center, Shreveport, LA, USA., Alpaugh ES; Department of Anesthesiology, Louisiana State University Health Science Center New Orleans, LA, USA., Lawson J; Department of Emergency Medicine, Louisiana State University Health Science Center, Shreveport, LA, USA., Apgar TL; Department of Chemical Biology and Biochemistry, Vanderbilt University, Nashville, TN, USA., Imani F; Pain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran., Khademi SH; Department of Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran., Cornett EM; Department of Anesthesiology, Louisiana State University, Shreveport, LA, USA., Kaye AD; Department of Anesthesiology, Louisiana State University, Shreveport, LA, USA.
Jazyk:	angličtina
Zdroj:	Anesthesiology and pain medicine [Anesth Pain Med] 2022 May 09; Vol. 12 (2), pp. e126416. Date of Electronic Publication: 2022 May 09 (Print Publication: 2022).
DOI:	10.5812/aapm-126416
Abstrakt:	Over the last several decades, opioid diversion, misuse, and over-prescription have run rampant in the United States. Spinal cord stimulation (SCS) has been FDA approved for treatment for a primary indication of neuropathic limb pain that is resistant to more conservative medical therapy. The disorders qualified for treatment include neuropathic, post-surgical, post-amputation, osteodegenerative, and pain related to vascular disease. Some of the most frequently cited conditions for treatment of SCS include failed back surgery syndrome, complex regional pain syndrome (CRPS) Type I and Type II, and post-herpetic neuralgias. Developments in SCS systems have led to the differentiation between the delivered electromechanical waveform patterns, including tonic, burst, and high-frequency. Burst SCS mitigates traditional paresthesia due to expedited action potential and offers improved pain relief. Burst SCS has been shown in available studies to be non-inferior to the traditional SCS, which can cause pain paresthesia in patients who already have chronic pain. Burst SCS does not seem to cause or need the paresthesia seen in traditional SCS, making SCS not tolerable to patients. Moreover, some studies suggest that burst SCS may decrease opioid consumption in patients with chronic pain. This can make burst SCS an extremely useful tool in the battle against chronic pain and the raging opioid epidemic. As of now, more research needs to be performed to further delineate the effectiveness and long-term safety of this device. Competing Interests: Conflict of Interests: The authors have no conflicts of interest to disclose, in terms of funding and research support, employment, personal financial interest, patents, and consultation fees within the last five years. One of the authors (F. I.) is EIC, and the other (S. H. K.) is one of the reviewers of this journal. Based on journal policy these two authors were completely excluded from any review of this article. (Copyright © 2022, Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu